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Background: The present study was designed to study anxiolytic property of methanolic extracts of Urtica urens;
an important and commonly used for its medicinal properties belongs to urticaceae family.
Methods: The anxiolytic activity was evaluated with the adult mice by hole board test, and the light–dark box test,
and motor coordination with the rota rod test. The efficacy of the plant extract (100–400 mg/kg) was compared
with the standard anxiolytic drug diazepam (1 mg/kg i.p.)
Results: The extract increased the time spent in the brightly-lit chamber of the light/dark box, as well as in the
number of times the animal crossed from one compartment to the other. Performance on the rota rod was
unaffected. In the hole board test, the extract significantly increased both head-dip counts and head-dip duration.
Urtica urens, in contrast to diazepam, had no effect on locomotion.
Conclusions: These results provides support for anxiolytic activity of Urtica urens, in line with its medicinal
traditional use, and may also suggest a better side-effect profile of Urtica urens relative to diazepam.
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Being anxious throughout life has implications not just
for subjective wellbeing, but also for physical health and
longevity [1]. Anxiety is an unpleasant state of inner tur-
moil, often accompanied by nervous behavior, somatic
complaints and rumination [2], when anxiety becomes
excessive, it may be considered as an anxiety disorder,
and can critically decrease the quality of life inducing
several psychosomatic diseases.
This class of disorders, which includes Agoraphobia,
Specific Phobia, Social Anxiety Disorder (Social Phobia),
Panic Attack, Separation Anxiety Disorder, and Selective
Mutism [3], Anxiety is defined as “a state of intense ap-
prehension, uncertainty, and fear resulting from the an-
ticipation of a threatening event or situation, often to a
degree that normal physical and psychological functioning
is disrupted” [4], The American Psychiatric Association
(APA) purports that each of the Anxiety Disorders share* Correspondence: d.zouhra@yahoo.fr
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unless otherwise stated.features of fear and anxiety. “Fear is the emotional
response to real or perceived threat, whereas anxiety is
anticipation of future threat” [3].
Approximately two-thirds of the anxious patients
respond to the currently available treatments but the
magnitude of improvement is still disappointing, besides,
they also produce various systemic side effects and exhibit
dependence and tolerance on chronic treatment which now
have become a major concern about the use of currently
used medicines [5].
Anxiolytic substances mostly belonging to the benzo-
diazepines group, occupy a prominent post in the ranking
of the most utilized drugs of man [6], These Classical ben-
zodiazepines act via the benzodiazepine receptors which
are present on the GABAA pentameric complex. The
most used compound is diazepam (52% of the studies in-
vestigating the action of a benzodiazepine full agonist) [7].
However, the clinical uses of benzodiazepines are limited
by their side effects such as psychomotor impairment,
sedation, myorelaxation, ataxia, amnesia, potentiation of
other central depressant drugs and dependence liability
[8,9], there is a need of drug which possesses greaterl. This is an Open Access article distributed under the terms of the Creative
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tolerance and dependence. Herbs are widely accepted
sources of medicine, which play an important role in
health care programme worldwide [10]. Hense numerous
tradionally used plants exhibit pharmacological properties
with great potential for therapeutic applications in the
treatment of central nervous system disorders, such as
anxiety disorders [11,12]. Also because of the increasing
desire of people to use herbal medicines in this study been
try to anti-anxiety effect of Urtica urens (medicinal plant
used in folk medicine in Morocco), researchers in Africa
particularly in morocco are exploring the traditional remed-
ies to find a suitable cure for these mind affecting diseases.
Moreover, Moroccan climate and favored geographical lo-
cation have contributed to diversity of medicinal plants.
In Morocco, four species of Urtica which belongs to the
Urticaceae family are available [13]. Urtica urens com-
monly known as a herbaceous annual plant species of the
genus Urtica, and has long been known to have tranquil-
lizing effects among the Moroccan people [14]. This Small
nettle
(Urtica urens) has anti-inflammatory effect [15], nettle
and their hybrids or mixtures are recommended for
symptomatic treatment of rheumatoid arthritis or
osteoarthritis and for increased dieresis [16]. Main con-
stituents identified in the plant material are flavonoids,
caffeoyl-esters, caffeic acid, scopoletin (cumarin), sitosterol
(−3-O-glucoside), polysaccharides, fatty acids (e.g. 13-
hydroxyoctadecatrienoic acid), minerals (herba: up to
20%; leaves: 1–5%) [17,18].
Despite the wide spread use of Urtica urens as an anxio-
lytic, there are no pharmacological data to support this,
and therefore we undertook the study to evaluate the
anxiolytic potential the methanolic extract of Urtica urens
by using a battery of appropriate rodent test models.
Materials and methods
Animals
Adult Swiss mice (20–30 g) of either sex were used for
the study. The animals were acquired from the animal
experimental centre of Mohammed V souissi University,
Medicine and pharmacy Faculty, Rabat. The animals
were maintained in a room with controlled temperature
(25 ± 1°C) and lighting (light/dark 12:12 h in polypropyl-
ene cages, with food and water ad libitum. Animals were
acclimatized to laboratory conditions at least 1 h prior
to initiation of experiments. The animals were divided
into four groups, each consisting of six mice, imple-
mented in all sets of experiments.
Plant material
The aerial part of Urtica urens was collected in April
2013 from the north of Morocco near the town of Wazzan
(Jaaouna el Basra), with assistance of a traditional medicalpractitioner. The plant was authenticated by botanists
of scientific institute Pr. M. Ibn Tatou and Pr. Halim
Khammar. A voucher specimen (N° RAB78983) was de-
posited in the Herbarium of Botany Department of the
Scientific Institute of Rabat.
Preparation of the methanolic extract
The aerial part was dried at room temperature and
crushed. 700 g of plant material was extracted with six
liter of methanol by maceration at room temperature
(25°C) over period of 48 hours. Methanol containing the
extract was then filtered through Whatman paper and
the solvent was vacuum-distilled at 60°C in a rotary
evaporator. The remaining extract was finally dried by
desiccator. Final extract was a dark green paste, with
11.92% dry weight. The residue was dissolved in water
for final suitable concentrations.
Drugs
The methanolic extract of Urtica urens was suspended
in distilled water. Diazepam (ampoule 10 mg/2 ml),
pharmacy of Avicenna) was diluted with saline to the re-
quired concentration before use. It is well known that
benzodiazepines act as anxiolytics at low doses and that
they induce sedation and muscle relaxant effects at higher
doses [19]. Therefore, we used diazepam (1 mg/kg) as a
positive control for anxiolytic-like effects.
Treatment schedule
Experimental groups of mice were treated orally (p. o.)
with methanolic extract of Urtica urens at doses of (100–
400 mg/kg), whereas control groups received normal
saline by the same routes. Diazepam (1 mg/kg) was ad-
ministered intraperitoneally (i.p.). All drugs were freshly
prepared before each experiment. The doses of extracts
were calculated to administer 0.25 ml of the suspension of
extracts to the mice of 20 g. The trial was carried out
30 min after the treatments. The anxiolytic activity was
examined by using the light/dark box test and the hole
board test, and motor coordination test assessed with the
rota rod test.
Acute toxicity study
The procedure was followed as per OECD 423 guide-
lines [20] (OECD/OCDE. 2002). The extract was admin-
istered orally at a dose of 2000 mg/kg body weight. Mice
were kept under observed for 14 days to register possible
mortality; their weights were registered and study their
behavioral neurological toxicity.
Light/dark test
The apparatus consisted of two 20 cm × 10 cm × 14 cm
plastic boxes: one light compartment painted white and
brightly illuminated and the other was dark painted
Table 1 Light/dark test
Treatment Dose (mg/kg) Time in the
light box
No. of transition
Saline 72.98 ± 18.39 10.5 ± 1.910
Diazepam 1 193.4 ± 17.00** 8.5 ± 1.928
Plant extract 100 120.6 ± 24.03 12.33 ± 3.383
Plant extract 200 156.8 ± 24.23* 12.17 ± 1.682
Plant extract 400 83.62 ± 9.96 16.00 ± 0.577
All values are mean ± SEM (n = 6); *p < 0.05, **p < 0.01 when compared to
control. One- way ANOVA, Tukey Kramer post hoc test.
Table 2 Hole board test
Treatment Dose (mg/kg) Number of head dipping
Saline 10.50 ± 1.3
Diazepam 1 14.83 ± 1.6*
Plant extract 100 14.33 ± 3.3
Plant extract 200 31.5 ± 2.8***
Plant extract 400 17.20 ± 1.5*
All values are mean ± SEM (n = 6); *p < 0.05, ***p < 0.001 when compared to
control. One- way ANOVA, Tukey Kramer post hoc test.
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were allowed to move from one box to the other
through an open door between the two boxes. The illu-
mination in the black compartment was 50 lux, in the
white area it was increased to 1000 lux, generated by an
extra light source. A mouse was put into the light box
facing the hole. The transition between the light and the
dark box and time spent in the light box were recorded
for 5 min.
Hole board test
The hole board test [21] was adopted in this test. It is
made of gray Perspex. The LETICA board (signo 720;
Printer LE 3333) of dimensions 40 cm × 40 cm, contained
16 evenly spaced holes (3 cm diameter and 2.2 cm depth),
with in-built infra-red sensors was used for the study. The
matt finishing of the upper panel avoids reflections which
may alter the animal behavior. An animal was placed in
the center of the hole board and allowed to freely explore
the apparatus for 5 min. The number of times an animal
dipped its head into the holes was automatically counted
and recorded by the instrument [22].
Rota rod test
The effect on motor coordination was assessed using a
rota-rod apparatus (LE 8500). Rota rod consisted of a
base plant form and aniron rod of 3 cm diameter and
30 cm length, with a non-slippery surface. The rod was
divided into four equal sections by three disks. The ani-
mals were pre-selected in a training session 24 h before
the test, based on their ability to remain on the bar (at
12 rpm) for 2 min, and then allowing four mice to walk
on the rod at the speed of 12 rpm at the same time ob-
served over a period of 30, 60, and 90 min. Intervals be-
tween the mounting of the animal on the rotating bar
and falling off of it were registered automatically as the
performance time. Time spent in the apparatus was ob-
served for 5 min duration (300 s).
Apparatus was cleaned thoroughly between trials with
water. All behavioral recordings were carried out with the
observer blind to the treatment the mice had received.
Statistical analysis
All results are expressed as mean ± standard error of the
mean. The data were analyzed statistically using one way
analysis of variance ANOVA, followed by the Tukey
Kramer post hoc test for multiple comparisons. P < 0.05




Following oral administration methanolic extract of
Urtica urens at a dose of 2000 mg/kg, P.O., animals wereobserved for signs of toxicity such as convulsions,
hypothermia, hyperactivity, and grooming continuously
for 2 h and for mortality up to 24 h after administration
of the doses. No toxicity and no significant changes in
the body weight were observed between the treated and
control group.
Light/dark test
Urtica urens at the dose of 200 mg/kg and diazepam
(1 mg/kg) induced a significant increment of the time
spent by mice on the illuminated side of the apparatus
compared to the respective control group (P <0.05,
P <0.01), without significantly affecting other parameters
(Table 1).
Hole board test
The dose 200 mg/kg of the plant extract significantly in-
creased the number of head dippings as compared to
control animals (Table 2).
Rota rod test
The data shows that on average the mice treated with
100, 200 and 400 mg/kg p.o. of the methanolic extract of
Urtica urens were able to maintain equilibrium on the
rotating rod and stayed on longer without falling (Table 3).
Whereas diazepam (at 1 mg/kg only) showed a significant
decrease in the locomotor score when compared to other
groups.
Discussion
In the therapy of anxiety disorder or acute anxiety
symptoms, a combination of therapeutic interventions
Table 3 Rota rod test
Treatment Dose (mg/kg) Time (sec) of animals remained without falling from rod
30 min 60 min 90 min
Saline 1 ml 300 300 300
Diazepam 1 92.33 ± 22,45*** 199.8 ± 35,34* 217.5 ± 32.58
Plant extract 100 227 ± 33.87 260,7 ± 18.39 265.2 ± 31.19
Plant extract 200 262.5 ± 22.48 264.8 ± 22.99 277.2 ± 22.83
Plant extract 400 240.2 ± 34.51 270.1 ± 17.25 280.1 ± 19.90
All values are mean ± SEM (n = 6); *p < 0.05, ***p < 0.001 when compared to control. One- way ANOVA, Tukey Kramer post hoc test.
Effect of methanolic extract of Urtica Urens and diazepam on motor coordination (rota-rod performance) of mice
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proach, anxiolytics are a part of treatment of anxiety
[23]. Dysregulation of the GABAergique, serotoninergic,
dopaminergic and adrenergic neurosystems have all
been implicated in the pathophysiology of anxiety [24].
Benzodiazepines are the most widely prescribed for the
last 40 years to treat several forms of anxiety; however,
they have prominent side effects such as sedation, myore-
laxation, ataxia and amnesia, and can cause pharmaco-
logical dependence [25]. Other anti-anxiety medications
include antidepressants, buspirone and β -blockers which
though effective in many cases, also possess side effects like
nausea, light headedness, dizziness, headache, dry mouth,
constipation, diarrhea, etc. [26].
Self-administration of herbal medicines was among the
most popular of alternative therapies, there is considerable
interest in the development of new anxiolytics, new therapies
for the treatment of anxiety disorders are necessary, and
the study of medicinal plants could provide new therapeutic
options [12].
In the current work we examined the anxiolytic effects
of methanolic extract of Urtica urens, using the light/
dark test and the hole board, and to examine motor
coordination we used Rota rod test. Furthermore, the
effects of Urtica urens and diazepam on these animal
models were compared to determine whether the behav-
ioral profile Urtica urens differed from an established
anxiolytic drug.
In the light/dark test, anxiety is generated by the con-
flict between the tendency to explore and the initial ten-
dency to avoid the unfamiliar [27] and can be evaluated
according to the number of transitions in to and the
time spent in the light chamber [28,29] where in increase
in these parameters is considered to reflect anxiolytic-like
properties. Our results showed that the extract (200 mg/kg)
increased time spent in the light chamber, suggesting
anxiolytic action.
The hole board test is useful for modeling anxiety in an-
imals, in this test an anxiolytic-like state may be reflected
by an increase in head –dipping behaviors [30,31]. Our
results showed that methanolic extract (200 mg/kg) of
urtica urens increased the head dipping corroborating theanxiolytic-like effect previously shown in the light- dark
test.
Rota rod test a classical animal model used to evaluate
peripheral neuromuscular blockade and the motor co-
ordination [32], a deficit in motor coordination would
very likely affect performance in the behavioral tests.
Our findings showed that Urtica urens (100-200 mg/kg),
unlike diazepam (1 mg/kg), had no significant effect
on motor coordination. Furthermore, the extract didn’t
affect motor coordination, is additional evidence of cen-
trally mediated actions and not blockade of neuromus-
cular system [21,33]. The Urtica urens extract showed
promising anxiolytic effects without causing any neuro-
muscular side effects.Conclusion
The data presented hereby reinforce the traditional use
of Urtica urens by Moroccan people to treat anxiety
[14]. Despite the wide spread traditional use of Urtica
urens for treating various disorders there are no reports
of scientific evaluation of its anxiolytic activity.
Our study shows that the Urtica urens extract had marked
effects on the anxiety-related behavioural parameters on
exposure to the light/dark test and the hole board in mice.
Urtica urens extract causes an “anxiolytic” behaviour
comparable with the effects of diazepam.
Future studies will be focused on the neurobiological
mechanisms of action and possible interactions of Urtica
urens with classical neurotransmitters and the phytocon-
stituent(s) responsible for the observed central effects
has to be isolated and identified.Competing interests
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